Literature DB >> 20849306

Retrograde ureteroscopic treatment for upper ureteral stones: a 5-year retrospective study.

Weimin Yu1, Fan Cheng, Xiaobin Zhang, Sixing Yang, Yuan Ruan, Yue Xia, Ting Rao.   

Abstract

PURPOSE: To review our 5-year experience with retrograde ureteroscopic treatment for patients with upper ureteral stones and to compare the outcome, safety, and efficiency of pneumatic and holmium laser lithotripsy in managing upper ureteral stones. PATIENTS AND METHODS: We retrospectively analyzed the hospital records of 372 patients who underwent 384 retrograde ureteroscopic procedures for upper ureteral stones at our center from January 2003 to December 2007. Patient and stone characteristics, treatment variables. and clinical outcomes were assessed. Factors such as failure of the procedure, stone clearance, intraoperative and postoperative morbidity, procedure duration, and hospital stay were analyzed and compared between pneumatic (group 1) and laser lithotripsy (group 2).
RESULTS: Overall, the stone-free rate was 90.4%, the mean operative duration was 41.2 ± 10.7 minutes, the mean postoperative hospital stay was 2.7 ± 0.9 days, and the rates of intraoperative and postoperative complications were 14.6% and 3.9%, respectively, for groups 1 and 2. In comparing group 1 and group 2, the significantly higher number of intraoperative complications coincide with a significantly lower stone-free rate. Nevertheless, the incidence of intraoperative and postoperative complications between the two groups was not statistically significant except in the case of stone upward migration. The mean operative time of group 2 was 43.3 ± 11.1 minutes, which was significantly longer than that for group 1, which was 38.7 ± 9.1 minutes (P < 0.05).
CONCLUSION: Retrograde ureteroscopy is a safe and effective method for managing upper ureteral stones. A high postoperative stone-free rate is associated with the refined use of a holmium laser lithotriptor to ensure thoroughness while avoiding migration of the stones into the renal pelvis. Although laser lithotripsy has a longer operative time, it remains the more appropriate choice for managing upper ureteral stones.

Entities:  

Mesh:

Year:  2010        PMID: 20849306     DOI: 10.1089/end.2009.0611

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  6 in total

1.  Does a retropulsion prevention device equalize the surgical success of Ho:YAG laser and pneumatic lithotripters for upper ureteral stones? A prospective randomized study.

Authors:  Sahin Bagbanci; Mumtaz Dadali; Yeliz Dadalı; Levent Emir; Ozkan Gorgulu; Ayhan Karabulut
Journal:  Urolithiasis       Date:  2016-10-19       Impact factor: 3.436

2.  Ureteral wall thickness at the impacted ureteral stone site: a critical predictor for success rates after SWL.

Authors:  Kemal Sarica; Alper Kafkasli; Özgür Yazici; Ali Cihangir Çetinel; Mehmet Kutlu Demirkol; Murat Tuncer; Cahit Şahin; Bilal Eryildirim
Journal:  Urolithiasis       Date:  2014-11-25       Impact factor: 3.436

3.  Study of ureteral and renal morphometry on the outcome of ureterorenoscopic lithotripsy: The critical role of maximum ureteral wall thickness at the site of ureteral stone impaction.

Authors:  Amit Kumar Mishra; Santosh Kumar; Lalgudi Narayan Dorairajan; Ramanitharan Manikandan; G Ramkumar; K S Sreerag; Jayesh Kumar Mittal
Journal:  Urol Ann       Date:  2020-06-10

4.  Management of impacted proximal ureteral stone: Extracorporeal shock wave lithotripsy versus ureteroscopy with holmium: YAG laser lithotripsy.

Authors:  Mostafa Khalil
Journal:  Urol Ann       Date:  2013-04

5.  The effect of application of a Soton ureteroscope on infection after flexible ureteroscopy lithotripsy.

Authors:  Xiaobo Zhang; Zhenyu Liu; Xiong Chen; Dongjie Li; Zhiming Yang; Jie Gu; Sheng Hu; Yuxin Li
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2021-07-13       Impact factor: 1.195

6.  Endoscopic holmium laser treatment for ureterolithiasis.

Authors:  Zbigniew Purpurowicz; Marek Sosnowski
Journal:  Cent European J Urol       Date:  2012-03-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.